Skip to main content

Table 2 Relative changes in DCE-MRI parameters compared with baseline values at 1 h, 24 h, and 21 days after the first dose of bevacizumab in eight patients with breast cancer with brain metastases

From: A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer

Parameters

Baseline

Δ1 h(%)

Δ24 h(%)

Δ21 Days(%)

Peak

223.3 ± 47.2

−12.8 ± 4.6

−24.7 ± 7.9

−27 ± 8.6

Slope

1.5 ± 1.1

−46.6 ± 26.5

−65.8 ± 20.6

−52.8 ± 27.7

iAUC 60

49820 ± 31258

−27.9 ± 15

−55.5 ± 11.1

−58.1 ± 15

Ktrans (min -1  x 1000)

858.1 ± 1194.7

−46.6 ± 27.6

−63.9 ± 31.2

−78.2 ± 23.9

  1. Data are presented as the mean ± standard deviations (SD). The Wilcoxon signed-rank test had P < .01 compared with the baseline DCE-MRI data
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us